Inovio Pharmaceuticals (INO) Stock: Gains On Clinical Data

Inovio Pharmaceuticals Inc (NASDAQ: INO) is having a relatively strong start to the trading session this morning after the company reported positive data surrounding a key vaccine. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:09), INO is trading at $6.58 per share after a gain of $0.11 per share or 1.62% thus far today.

INO Gains On Positive Clinical Data

As mentioned above, Inovio Pharmaceuticals is having a relatively strong start to the trading session after the company released positive data surrounding a Phase 1 clinical trial. The data came from the trial of a vaccine designed to prevent the Zika virus. During the Phase 1 clinical trial, the company uncovered positive data with regard to both safety and immune response.

According to the press release offered by the company early this morning, the INO DNA-based Zika vaccine, known as GLS-5700, induced high levels of binding antibodies in 100% of the study’s participants. The company also informed investors that it observed robust neutralizing antibody and T cell immune repsonses in vaccinated subjects. The data was published in the New England Journal of Medicine in an article titled “Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine” that was created by INO researchers and collaborators.

During the study, Inovio Pharmaceuticals gave 40 participants GLS-5700 in either a 1 mg or 2 mg dose. The vaccine was administered in 0.1ml intradermal injections administered by Inovio’s CELLECTRA® 3P skin vaccine device. According to INO, the GLS-5700 Zika vaccine induced binding antibodies in 100% of the participants after a 3-dose vaccination regimen and in 95% after two doses of the vaccine. Also, neutralizing antibodies were observed in more than 95% of the serum samples that were assayed on neuronal-cell targets. From there, serum samples were injected into mice. This showed that more than 90% of the animals were protective from death and illness after they were challenged with a lethal dose of the Zika virus. In a statement, Dr. J. Joseph Kim, President and CEO at INO, had the following to offer:

Inovio is the first organization in the world to report on positive Zika vaccine data from a clinical study. We’ve posted similar encouraging HIV, Ebola and MERS vaccine data arising from our product development engine of DNA-immunotherapies and vaccines. Results from this published study demonstrate that all human subjects responded to the vaccine and that the immune responses have the ability to confer protection in challenge models. A second phase 1 study, now fully enrolled in Puerto Rico, is designed with a placebo control to explore a potential trend toward clinical efficacy. Inovio is proud to be a pioneer of Zika vaccine development, and the first to generate positive human data that clearly supports advancement of DNA technology and our vaccine candidate.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on INO. In particular, we’re interested in following their ongoing work, not just with the Zika vaccine, but with regard to the DNA-based vaccine approach in general. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Leave a Comment